K. T. Flaherty

874 total citations
32 papers, 644 citations indexed

About

K. T. Flaherty is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, K. T. Flaherty has authored 32 papers receiving a total of 644 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 13 papers in Oncology and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in K. T. Flaherty's work include Melanoma and MAPK Pathways (14 papers), Click Chemistry and Applications (6 papers) and Renal cell carcinoma treatment (6 papers). K. T. Flaherty is often cited by papers focused on Melanoma and MAPK Pathways (14 papers), Click Chemistry and Applications (6 papers) and Renal cell carcinoma treatment (6 papers). K. T. Flaherty collaborates with scholars based in United States, Italy and Greece. K. T. Flaherty's co-authors include Walter M. Stadler, Amita Patnaik, Mark J. Ratain, Brian Schwartz, Maryann Redlinger, Lynn M. Schuchter, P J O'Dwyer, M. Gore, Tim Eisen and James R. Wright and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

K. T. Flaherty

31 papers receiving 629 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
K. T. Flaherty United States	15	461	356	256	140	57	32	644
Christopher Moy United States	12	363 0.8×	270 0.8×	177 0.7×	161 1.1×	47 0.8×	17	618
Sujatha Nallapareddy United States	10	509 1.1×	440 1.2×	141 0.6×	122 0.9×	103 1.8×	16	790
Phillip Stahl Germany	13	395 0.9×	254 0.7×	243 0.9×	174 1.2×	121 2.1×	22	870
Anne-Marie Martin United States	4	396 0.9×	403 1.1×	215 0.8×	206 1.5×	66 1.2×	5	713
Jennifer Kahler United States	6	302 0.7×	300 0.8×	283 1.1×	79 0.6×	52 0.9×	10	561
Wai Lin Wong United States	2	461 1.0×	324 0.9×	163 0.6×	137 1.0×	113 2.0×	4	681
Mitchell D. Nambu United States	3	351 0.8×	286 0.8×	271 1.1×	76 0.5×	115 2.0×	3	648
Kerstin Trunzer Switzerland	10	236 0.5×	421 1.2×	270 1.1×	80 0.6×	54 0.9×	16	556
Brianne Kaiser United States	4	405 0.9×	227 0.6×	132 0.5×	97 0.7×	104 1.8×	4	607
Steve Bender United States	7	399 0.9×	259 0.7×	269 1.1×	148 1.1×	59 1.0×	9	650

Countries citing papers authored by K. T. Flaherty

Since Specialization

Citations

This map shows the geographic impact of K. T. Flaherty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. T. Flaherty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. T. Flaherty more than expected).

Fields of papers citing papers by K. T. Flaherty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. T. Flaherty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. T. Flaherty. The network helps show where K. T. Flaherty may publish in the future.

Co-authorship network of co-authors of K. T. Flaherty

This figure shows the co-authorship network connecting the top 25 collaborators of K. T. Flaherty. A scholar is included among the top collaborators of K. T. Flaherty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. T. Flaherty. K. T. Flaherty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Schadendorf, Dirk, Reinhard Dummer, K. T. Flaherty, et al.. (2023). 1113P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma. Annals of Oncology. 34. S670–S671. 3 indexed citations

2.

Corcoran, Ryan B., T. Khanh, James M. Cleary, et al.. (2023). 664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors. Annals of Oncology. 34. S467–S467. 1 indexed citations

3.

Haydon, Andrew, Dirk Schadendorf, Reinhard Dummer, et al.. (2023). 602P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma. Annals of Oncology. 34. S1707–S1708. 2 indexed citations

4.

Dummer, Reinhard, K. T. Flaherty, Caroline Robert, et al.. (2021). 1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma. Annals of Oncology. 32. S872–S873. 2 indexed citations

5.

Soumerai, Jacob D., Anthony R. Mato, Jason Carter, et al.. (2020). Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax.. Journal of Clinical Oncology. 38(15_suppl). 8006–8006. 15 indexed citations

6.

Corcoran, Ryan B., T. Khanh, James M. Cleary, et al.. (2019). Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours. Annals of Oncology. 30. v164–v164. 16 indexed citations

7.

Enderle, Daniel, Kay Brinkmann, Tina Koestler, et al.. (2014). 454 Monitoring therapy response and resistance mutations in circulating RNA and DNA of plasma from patients with malignant melanoma. European Journal of Cancer. 50. 149–149. 2 indexed citations

8.

Sharfman, William H., F. Stephen Hodi, Donald P. Lawrence, et al.. (2011). Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma.. Journal of Clinical Oncology. 29(15_suppl). 8508–8508. 38 indexed citations

9.

Flaherty, K. T.. (2010). Targeting signal transduction pathways in melanoma. Melanoma Research. 20. e20–e20.

10.

Cetnar, Jeremy, Mark Rosen, David J. Vaughn, et al.. (2009). Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 27(15_suppl). e16055–e16055. 9 indexed citations

11.

Sosman, Jeffrey A., K. T. Flaherty, Michael B. Atkins, et al.. (2008). Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). Journal of Clinical Oncology. 26(15_suppl). 5011–5011. 63 indexed citations

12.

Flaherty, K. T., Lia Gore, Anjali Narayan Avadhani, et al.. (2008). First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: Alvespimycin (A) administered QOD or Q. Journal of Clinical Oncology. 26(15_suppl). 2502–2502. 7 indexed citations

13.

Amaravadi, Ravi K., David F. McDermott, Amy Kramer, et al.. (2007). Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma. Journal of Clinical Oncology. 25(18_suppl). 8527–8527. 26 indexed citations

14.

Schiller, Joan H., et al.. (2006). Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis. Journal of Clinical Oncology. 24(18_suppl). 7194–7194. 42 indexed citations

15.

O’Dwyer, Peter J., Mark Rosen, Maryann Gallagher, Brian Schwartz, & K. T. Flaherty. (2005). Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology. 23(16_suppl). 3005–3005. 20 indexed citations

16.

Ratain, Mark J., Walter M. Stadler, K. T. Flaherty, et al.. (2005). Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology. 23(16_suppl). 4544–4544. 76 indexed citations

17.

Veronese, M L, K. T. Flaherty, Raymond R. Townsend, et al.. (2004). Pharmacodynamic study of the raf kinase inhibitor BAY 43–9006: Mechanisms of hypertension. Journal of Clinical Oncology. 22(14_suppl). 2035–2035. 1 indexed citations

18.

Ratain, Mark J., K. T. Flaherty, Walter M. Stadler, et al.. (2004). Preliminary antitumor activity of BAY 43–9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology. 22(14_suppl). 4501–4501. 38 indexed citations

19.

Flaherty, K. T., et al.. (2004). Phase I trial of imatinib and temozolomide in patients with metastatic melanoma. Journal of Clinical Oncology. 22(14_suppl). 7572–7572. 3 indexed citations

20.

Ratain, Mark J., K. T. Flaherty, Walter M. Stadler, et al.. (2004). Preliminary antitumor activity of BAY 43–9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology. 22(14_suppl). 4501–4501. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact